These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 36044214)

  • 1. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
    Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
    JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
    Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower rate of major bleeding in very high risk patients undergoing left atrial appendage occlusion: A propensity score-matched comparison with direct oral anticoagulant.
    Magnocavallo M; Della Rocca DG; Vetta G; Mohanty S; Gianni C; Polselli M; Rossi P; Parlavecchio A; Fazia MV; Guarracini F; De Vuono F; Bisignani A; Pannone L; Raposeiras-Roubín S; Lochy S; Cauti FM; Burkhardt JD; Boveda S; Sarkozy A; Sorgente A; Bianchi S; Chierchia GB; de Asmundis C; Al-Ahmad A; Di Biase L; Horton RP; Natale A
    Heart Rhythm; 2024 Aug; 21(8):1267-1276. PubMed ID: 38246567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
    Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
    JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of CAS risk model and CHA
    Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
    [No Abstract]   [Full Text] [Related]  

  • 9. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA
    Nielsen PB; Skjøth F; Overvad TF; Larsen TB; Lip GYH
    Circulation; 2018 Feb; 137(8):832-840. PubMed ID: 29459469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHA
    Parsons C; Patel SI; Cha S; Shen WK; Desai S; Chamberlain AM; Luis SA; Aguilar MI; Demaerschalk BM; Mookadam F; Shamoun F
    Mayo Clin Proc; 2017 Mar; 92(3):360-369. PubMed ID: 28259228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany.
    Wicke FS; Schaller MA; Karymova K; Beyer M; Müller BS
    BMC Cardiovasc Disord; 2019 Apr; 19(1):94. PubMed ID: 31014253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.
    Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ
    Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
    Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):681-691. PubMed ID: 37580139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHA
    Kim TH; Yang PS; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Stroke; 2017 Jun; 48(6):1524-1530. PubMed ID: 28455320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHA
    Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation.
    Mehta HB; An H; Ardeshirrouhanifard S; Raji MA; Alexander GC; Segal JB
    Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008951. PubMed ID: 36453260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.